| Name
|
Brain Natriuretic Peptide (BNP) (1-32), Human
|
| Other Name
|
Brain Natriuretic Peptide(1-32), human
|
| Sequence (Single letter abbreviations)
|
SPKMVQGSGCFGRKMDRISSSSGLGCKVLRRH (Disulfide bridge: 10-26)
|
| Sequence（Three letter abbreviations）
|
{SER}{PRO}{LYS}{MET}{VAL}{GLN}{GLY}{SER}{GLY}{CYS}{PHE}{GLY}{ARG}{LYS}{MET}{ASP}{ARG}{ILE}{SER}{SER}{SER}{SER}{GLY}{LEU}{GLY}{CYS}{LYS}{VAL}{LEU}{ARG}{ARG}{HIS}
|
| Chemical bridge
|
Disulfide bridge: Cys10-Cys26
|
| Basic description
|
HIV-1 TAT Protein Peptide is known to be a protein and particle transduction domain (PTD) and at the same time to comprise a nuclear localization function (NLS). Oligomers of the TAT (47-57) peptide compact plasmid DNA to nanometric particles and stabilize DNA towards nuclease degradation. At optimized vector compositions, these peptides mediate gene delivery to cells in culture six to eight times more efficiently than poly-L-arginine or the mutant TAT2-M1.
|
| Solubility
|
The peptide is soluble in water. The contents of this vial have been accurately determined. Both the stopper and the vial have been siliconized. Do not attempt to weigh out a smaller portion of the contents.
|
| The molecular weight
|
3464.100
|
| Chemical formula
|
C143H244N50O42S4
|
| The purity
|
> 95%
|
| Storage conditions
|
Store the peptide at -20°C.
|
| Annotation
|
|
| Documents
|
|
| Figures
|
|
| Reference
|
Prontera C, et al. Comparison of a fully automated immunoassay with a point-of-care testing method for B-type natriuretic peptide. Clin. Chem. Jul 2005; 51(7): 1274-1276.
Brandt I, et al. Dipeptidyl-peptidase IV converts intact B-type natriuretic peptide into its des-SerPro form. Clin. Chem. Jan 2006; 52(1): 82-87.
|
Brain Natriuretic Peptide (BNP) (1-32), Human
